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EDITORIAL
Transforming growth factor b1 and renal disease in African
Americans
In this issue of Kidney International, Suthanthiran et al [1] suggest
a novel hypothesis to explain the greater incidence of end-stage
renal disease (ESRD) in African Americans as compared to
Caucasians in the United States. They postulate that the increased
risk of renal disease and its progression to ESRD in African
Americans is related to an increase in the production and
circulating levels of transforming growth factor-b (TGF-b).
TGF-b, a multifunctional cytokine discovered about 20 years ago
[2,3], plays an important role in embryonic development and in
regulating repair and regeneration after tissue injury [4,5]. It is
also involved in angiogenesis, regulation of inflammation, control
of cell proliferation, cell adhesion, protease activity, and pheno-
typic change. Although the TGF-b family of molecules is multi-
functional, their major role appears to be as inhibitors of cell
growth and enhancers of matrix formation. Five distinct isoforms
of TGF-b have been described and three of these, TGF-b1,
TGF-b2, and TGF-b3, are found in all mammalian tissues. The
gene for each isoform is located on a different chromosome and
has a distinct 59 flanking sequence regulating its expression.
Biologically active TGF-b1 is a 25 kD protein composed of two
subunits linked by a disulfide bond. This protein is secreted in an
inactive (latent) form that requires processing before it can exert
its effect. Latent TGF-b1 is stored at the cell surface and the
extracellular matrix and is converted to active TGF-b1 by mech-
anisms not well understood [6,7].
Active TGF-b1 increases matrix synthesis, inhibits matrix deg-
radation, upregulates the integrin-matrix adhesion factors and is a
chemoattractant for fibroblasts and macrophages [4,8]. It also
stimulates fibroblast proliferation [9]. TGF-b affects a number of
components of the extracellular matrix such as fibronectin, colla-
gens I, II, III, IV and VI, osteopontin, proteoglycans (decorin,
biglycan), SPARC and osteonectin. TGF-b1 inhibits matrix deg-
radation by increasing the activity of tissue inhibitors of metallo-
proteinases (TIMPs) and decreasing the activity of metallopro-
teinases. It also stimulates the synthesis of receptors for
extracellular proteins.
In several experimental models of glomerulonephritis, such as
anti-glomerular basement membrane (GBM) nephritis, puromy-
cin induced nephrotic syndrome, diabetic glomerulopathy and
Thy-1 glomerulonephritis, TGF-b is upregulated in the glomeru-
lus. This cytokine is also upregulated in human nephropathies,
such as IgA nephropathy, lupus nephritis, focal segmental glomer-
ulosclerosis, and diabetic nephropathy [5,10].
Suthanthiran et al [1] found greater levels of “active” circulat-
ing (serum) TGF-b1 in 56 African Americans with ESRD when
compared to 42 white patients with ESRD. Renal production of
TGF-b1, either by intrinsic renal cells or invading macrophages,
has been implicated as a key mediator of tissue fibrosis in the
kidney. However, growing evidence indicates that circulating
TGF-b1 may play an important role in physiologic and pathophys-
iologic processes. Increased production of TGF-b1 in the liver of
transgenic mice was followed by hepatic fibrosis, myocarditis, and
renal disease [11]. In this mouse model, increased levels of
circulating TGF-b1 induced progressive renal disease character-
ized by mesangial expansion, accumulation of matrix proteins and
interstitial fibrosis [12]. Thus, chronically increased levels of
circulating TGF-b1 appear to induce progressive glomeruloscle-
rosis. Furthermore, local expression of TGF-b1 and TGF-b3
mRNAs did not differ in transgenic mice with diseased kidneys
from non-transgenic mice with normal kidneys, suggesting an
important pathogenetic role for circulating TGF-b1 [7]. The
source of circulating TGF-b1 is unknown, although recent studies
in the TGF-b1 null mouse suggest that it may originate from the
bone marrow. It should be added that, thus far, detectable levels
of circulating TGF-b2 or -b3 have not been found, indicating
perhaps that these isoforms may act mainly as local autocrine or
paracrine factors.
Several observations indicate that increased or decreased levels
of TGF-b1 in plasma may correlate with certain pathological
changes. In this respect, increased levels of TGF-b1 have been
shown to be a good marker of invasive prostatic adenocarcinoma
[13]. In patients with breast cancer, an elevated level of TGF-b1 is
a predictor for hepatic and lung fibrosis, following bone marrow
transplantation [14]. Elevated plasma levels of TGF-b1 are found
in patients with thrombotic thrombocytopenic purpura [15]. On
the other hand, decreased levels of plasma TGF-b1 correlate
strongly with the presence of atherosclerosis [16].
Regarding the progression of renal disease, a plausible hypoth-
esis may be as follows: Thrombospondin 1 (TSP1) activates the
latent TGF-b in tissues. Angiotensin II induces TGF-b and TSP1
[17,18] and TSP1 precedes and predicts the presence of renal
fibrosis [19]. Activation of TGF-b further stimulates endothelin 1
production [20], which is also a strong accelerator of glomerulo-
sclerosis and fibrogenesis [21]. If circulating levels of TGF-b are
higher in African Americans with ESRD, they may be precondi-
tioned for a stronger fibrogenic response when local angiotensin
II has been engaged following renal injury.
The observations of Suthanthiran et al [1] and those of others
[13–15] indicate the need to explore in more detail the role of
circulating levels of TGF-b1 in the pathogenesis of hepatic and
lung fibrosis as well as the development of progressive renal
disease. The potential mechanisms by which increased circulating
levels of TGF-b1 occur in African Americans as compared to
Caucasians with ESRD also require additional study. It would be
advisable to examine the levels of circulating TGF-b1 and endo-
thelin in African Americans and whites with progressive renal
disease prior to ESRD, as well as in renal diseases characterized
by a rapid course (rapidly progressive glomerulonephritis).
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